One study demonstrated ERRγ-induced resistance to tamoxifen (TAM) in ER+ breast cancer models, and that the transcriptional activity of this receptor is modified by activation of the ERK/MAPK pathway [44]. Here, ESR1 is linked to breast carcinoma.